Physicians' Academy for Cardiovascular Education

HDL: moving forward after disappointing results with HDL-mimetic in CARAT study.

Mar. 19, 2017 - Prof. Stephen J. Nicholls - Adelaide, Australia

BET inhibition in renal and cardiovascular disease: What is the clinical roadmap?

June 5, 2017 - ERA-EDTA, Madrid Spain - Kamyar Kalantar-Zade, MD UC Irvine School of Medicine Irvine, Ca, USA

Molecular mechanisms involved in the beneficial effect of BET inhibition in experimental renal disease

June 5, 2017 - ERA-EDTA, Madrid Spain - Marta Ruiz-Ortega – Fundación Jiménez Díaz, Madrid, Spain

The high risk diabetes patient: What is the need for novel approaches to reduce cardiovascular and renal risk?

June 5, 2017 - ERA-EDTA, Madrid Spain - Luis M Ruilope, MD – Hospital 12 de Octubre, Madrid, Spain

UK: Clinical Dialogues: Lipids & Diabetes 2017

Dec. 7, 2017 - Stratford Upon Avon, United Kingdom - Prof Peter Sever

PCSK9 inhibition works, but you can’t force biology

Mar. 17, 2017 - Prof. Wouter Jukema – Leiden University Medical Center, The Netherlands - ACC 2017, Washington DC, USA

Identification of patients who will benefit is important after FOURIER

Mar. 19, 2017 - Prof. Ulf Landmesser - Charité - Universitätsmedizin Berlin, Germany - ACC 2017, Washington DC, USA

Landmark study with PCSK9 inhibitor will change clinical practice

Mar. 18, 2017 - Prof. Eric Bruckert - Pitié-Salpêtrière Hospital, Paris, France - ACC 2017, Washington DC, USA

Nanotherapeutic solutions to reduce atherosclerotic processes in the blood vessel

Mar. 16, 2017 - VBWG - ACC 2017 - John Cooke, MD, PhD - Houston, TX, USA

How incretin therapy changes diabetes and prediabetes management

May 22, 2017

HIV as a model to study effect of chronic inflammation on CV risk

Mar. 16, 2017 - VBWG ACC 2017

Lowering inflammation to address residual CV risk

Mar. 17, 2017 - Dr. Paul M. Ridker - Boston, MA, USA

Type of glycemic control is more important than tight glycemic control

May 1, 2017 - ESC HF 2017, Paris

Changing therapeutic behaviour after FOURIER

Mar. 18, 2017 - Prof. Wolfgang Koenig - Munich, Germany - ACC 2017, Washington DC, USA

Step forward in telemonitoring through use of an algorithm that risk-stratifies HF patients

May 31, 2017 - ESC HF 2017, Paris

Emerging therapeutic areas in lipid management and CV disease

Mar. 16, 2017 - VBWG - ACC 2017 - Sotirios Tsimikas - La Jolla, CA, USA

Disappointing results with therapy for acute heart failure

Apr. 30, 2017 - ESC HF 2017, Paris

Initiating digoxin in AF patients associated with early hazard of sudden death

Mar. 19, 2017 - ACC 2017, Washington, DC, USA - Dr. Renato Lopes

Challenges in Heart Failure management: Diabetes and Renal Impairment

May 12, 2017 - Paris, France - Martin Cowie, MD - ESC Heart Failure, Paris

The implications of PCSK9 outcome trials for GPs

Mar. 19, 2017 - Prof. Richard Hobbs – Oxford, United Kingdom - ACC 2017, Washington DC, USA

HFmrEF resembles HFrEF rather than HFpEF regarding IHD

June 28, 2017 - Vedin O, et al. - Circ Heart Fail. 2017

In the Swedish Heart Failure Registry, HFmrEF resembled HFrEF rather than HFpEF with respect to IHD as underlying cause, and IHD was a poor prognostic factor in all these 3 HF subtypes.

GLP-1 analogue approved by FDA for treatment diabetes

June 28, 2017 - news

Based on the results of the LEADER trial, GLP-1 analogue liraglutide is approved by the FDA to treat patients with type 2 diabetes.

Worse survival when using lower than recommended doses of ACEi/ARBs or beta-blockers in heart failure

June 28, 2017 - Ouwerkerk W, et al. - Eur Heart J, 2017

In the BIOSTAT-CHF study, reaching less than 50% of the ESC guideline recommended dose of ACE-inhibitor/ARB or beta-blocker doses was associated with worse survival in HF patients.

CETP inhibitor meets primary endpoint in CV outcome study

June 27, 2017 - news

Treatment with anacetrapib, in addition to atorvastatin, reduced major coronary events in patients at risk for cardiac events in the REVEAL study.

Long-acting statins are also effective when taken in the morning

June 27, 2017 - Awad K, et al. - J Clin lipidol 2017

Short-acting statins are significantly more effective in lowering LDL-C and total cholesterol when taken in the evening, but long-acting statins are equally effective when taken in the morning and evening.

HDL: moving forward after disappointing results with HDL-mimetic in CARAT study.

Mar. 19, 2017 - Prof. Stephen J. Nicholls - Adelaide, Australia
Prof. Stephen Nicholls indicates that because of the very different therapeutic approaches with respect to HDL, therapies still move forward, despite agents failing to demonstrate benefit.

Prof. Stephen Nicholls indicates that because of the very different therapeutic approaches with respect to HDL, therapies still move forward, despite agents failing to demonstrate benefit. The HDL mimetic CER-001, on top of a statin, showed no effect on plaque regression in post-ACS patients.

Evidence suggests proton-pump inhibitor can lower risk of severe GI bleeding in the elderly on antiplatelet therapy

June 26, 2017 - Li L et al. - Lancet 2017

In elderly patients on aspirin-based antiplatelet therapy without routine proton-pump inhibitor use, the long-term risk of disabling or fatal GI bleeding is 10 time higher, compared with younger age groups.

Anti-PCSK9-vaccination has anti-atherogenic effects in mice

June 26, 2017 - news

Anti-PCSK9 vaccination (AT04A) lowers LDL-c, atherosclerosis and inflammatory markers in mouse model for atherosclerosis. Phase I study into this vaccine has started

Investigational IL-1β-blocker targeting inflammation meets primary endpoint in outcome study

June 22, 2017
Phase III CANTOS study shows IL-1β-blocker ACZ885 (canakinumab), in addition to standard care, reduces CV events in people with prior myocardial infarction and inflammatory atherosclerosis

The phase III CANTOS study shows ACZ885 (canakinumab), in addition to standard care, reduces CV events in people with prior myocardial infarction and inflammatory atherosclerosis.

CV risk factors early in life associated with premature cognitive aging

June 22, 2017 - Rovio SP et al. - J Am Coll Cardiol 2017

In a population-based cohort, the cumulative burden of BP, serum total- and LDL-C, and smoking from childhood and adolescence, were independently associated with worse midlife cognitive performance.

Lower bleeding risk with NOACs vs VKA in low-risk AF patients

June 22, 2017 - Lip GYH et al. - JAMA Cardiol. 2017

In AF patients with a single non-gender-related stroke risk factor, the risk of any bleeding was lower for apixaban and dabigatran compared with warfarin, while no difference in stroke prevention was seen.

PCSK9 inhibition is associated with regression of tendon xanthomas in FH

June 21, 2017 - Bea AM et al. - Atherosclerosis 2017
In a case-control study on HeFH patients treated with potent statins, the addition of a PCSK9 antibody (evolocumab or alirocumab) resulted in a greater decrease of tendon xanthomas thickness after 3 years of treatment.

In a case-control study on HeFH patients treated with potent statins, the addition of a PCSK9 antibody resulted in a greater decrease of tendon xanthomas thickness after 3 years of treatment.